Dedicated to infectious disease solutions transparency global health collaboration innovation success our clients
We are a clinical research organisation
driving infectious disease products
Who are we and what is our expertise?
We strongly believe that early phase clinical trials can be designed to provide critical proof-of-concept data faster and more cost-efficient. Without compromising on quality, the INFECTA team takes pride in designing fit-for-purpose early phase clinical trials which aim to maximally derisk your clinical development path.
We provide a wide range of services for the development of vaccines, therapeutics, antivirals and biologics. We use and develop various clinical research methodologies and hold the largest global portfolio of controlled human infection models (CHIMs).
Emerging from the longstanding collaboration between four Dutch University Medical Centers and the Centre for Human Drug Research (CHDR), we have a strong legacy in early phase clinical research programs and a solid scientific foundation, including decades of experience with CHIMs.
How can we support you?
We can become your trusted partner during the clinical development of your infectious diseases’ compounds. We can provide support with the following activities:
Study set up
Stage
01
INFECTA offers a comprehensive setup phase for clinical trials, providing services such as study design, protocol writing, Clinical Trial Application (CTA) preparation, regulatory submission, volunteer recruitment, pharmacy services (including QP release), data management, statistics, pharmacometrics, and (e)TMF.
Study conduct
Stage
02
We conduct studies in a state-of-the-art, purpose-built facility, equipped with advanced technology and supported by a team of dedicated professionals, ensuring high-quality execution under ICH GCP guidelines and a seamless study experience.
Analysis and reporting
Stage
03
Our reporting and analysis services involve rigorous data review and statistical analysis, ensuring accurate interpretation of study results, and delivering clear, thorough clinical study reports that support informed decision-making.
Study close out
Stage
04
Our study close out services ensure the finalisation of all clinical activities, including data reconciliation, and regulatory documentation, ensuring compliance and a smooth transition to the next phase. Research will be conducted in compliance with registration standards, and is therefore appropriate for inclusion in the regulatory filing package.
Why choose INFECTA
Globally largest CHIM portfolio
Capacity to produce, establish and validate new CHIMs
Not-for-profit base with focus on social impact
Large academic network
Our controlled human infection models repository
Controlled human infection models (CHIMs) are powerful tools that can be used to study host-pathogen interaction in specific infections, as well as test efficacy of novel therapeutics and vaccines. CHIMs enable a swift and cost-efficient assessment of drug safety and efficacy early in clinical development, derisking your future clinical development path.
With decades of experience in performing CHIMs, the INFECTA team will carefully balance risks and benefits of these models for your product and give you insights into what you can or cannot learn from them. The INFECTA team manages the regulatory and operational complexities of these studies, selects the pathogen and has protocols available for the exposure and clinical follow up of the volunteers. Endpoints can be clinical, microbiological and immunological. We can ensure the consistence and robustness of the trials.
We already have an extensive portfolio of CHIMs, and are continuing to develop more. All CHIMs are developed in collaboration with our academic partners.
Bacteria
Our repository of CHIMs including Bordetella Pertussis and Pneumococcus provides a valuable platform.
Parasites
Viruses
Our CHIMs support research across a range of respiratory and vector-borne viruses, such as Dengue & Influenza
Our expertise lies in the pharmaceutical product development for infectious diseases with pandemic potential.
Company updates
14 – 16 October
World Vaccine Congress Europe 2025
With the launch of our extended website we gain the ability to showcase more information on our CHIMs repository, our services and our values. This reinforces our commitment to research on early phase clinical…
3 July, 2025
Our new website is live
With the launch of our extended website we gain the ability to showcase more information on our CHIMs repository, our services and our values. This reinforces our commitment to research on early phase clinical…